After receiving and reviewing nearly 600 entries spanning 10 award categories, Xconomy is thrilled to announce the 2020 Xconomy National Awards Finalists.
Since 2017, the mission of Xconomy’s annual awards programs has been to provide the industry a moment to... Read more »
The promise of gene therapies and gene-editing drugs is a long-lasting treatment that’s potentially a cure. But making permanent genetic changes means any accompanying problems could be long-lasting as well, says Omega Therapeutics CEO Mahesh Karande.
Omega is developing technology that... Read more »
Damage to axons, the slender tendrils through which nerve cells communicate, is an early indication of several neurological diseases. Nura Bio, which formed around new research into a mechanism underlying axonal degeneration, made its public debut Wednesday with a $73 million... Read more »
Thrive Earlier Detection, one of the companies vying to be the first to commercialize a blood test that can uncover cases of cancer before symptoms arise, has raised $257 million and announced plans to evaluate its CancerSEEK test in a registrational... Read more »
Pfizer and BioNTech’s COVID-19 vaccine research started with multiple approaches—four shots on the messenger RNA goal. The partners have narrowed their choices to one for pivotal testing, and that candidate takes the same tack as other companies trying to address... Read more »
Telemedicine isn’t just another way to connect patients with doctors. AristaMD has carved out a niche in connecting doctors with, well, other doctors.
The San Diego-based telehealth company’s software links primary care physicians and medical specialists through virtual consultations, communication that... Read more »
AstraZeneca’s partnership with Daiichi Sankyo led to FDA approval of an antibody cancer drug late last year. Now the British pharmaceutical giant is paying $1 billion up front to join forces on another antibody drug addressing a different cancer target.
The... Read more »
The lack of diversity in clinical trials is a serious problem that’s persisted for decades. Black Americans—who make up 20 percent of US multiple myeloma patients and are twice as likely to be diagnosed—have only accounted for 4.5 percent of... Read more »
The FDA on Friday approved a Gilead Sciences drug developed for treating mantle cell lymphoma, paving the way for the company to commercialize its second cancer cell therapy.
Approval for the drug, brexucabtagene autoleucel (Tecartus), covers patients whose cancer has relapsed... Read more »